期刊名称：NITRIC OXIDE-BIOLOGY AND CHEMISTRY
 期刊简介(About the journal)
投稿须知(Instructions to Authors)
编辑部信息(Editorial Board)
About the journal
Nitric Oxide: Biology and Chemistry
Nitric Oxide: Biology and Chemistry. Although one of the simplest biological molecules in nature, nitric oxide has found its way into nearly every phase of biology and medicine ranging from its role as a critical endogenous regulator of blood flow and thrombosis to a principal neurotransmitter mediating erectile function to a major pathophysiological mediator of inflammation and host defense. These major discoveries have stimulated intense and extensive research into a vast array of fields including chemistry, molecular biology, and gene therapy. Nitric Oxide: Biology and Chemistry provides a forum for the rapid publication of scientific investigation of the highest quality across the broad field of nitric oxide research.
|
Research Areas Include basic and clinical topics in:
Cell Biology
Molecular biology
Biochemistry
Immunology
Pathology
Genetics
Physiology
Pharmacology
Disease processes |
|
Instructions to Authors
Nitric Oxide: Biology and Chemistry is an international journal dedicated to the dissemination of fundamental knowledge in all areas of nitric oxide research. The journal features Original Contributions (peer-reviewed, high-quality research investigations representing new and significant contributions to basic and clinical science), Brief Reviews (peer-reviewed articles representing reviews of major areas within the field of nitric oxide research), Brief Communications (peer-reviewed brief studies that are highly significant and timely), Analytical Methods (peer-reviewed articles dealing with new methods of analysis involving nitric oxide), Hypothesis Articles (current state-of-the-art brief reviews of the frontier area of nitric oxide research), Current Trends (articles focusing on current and future directions of nitric oxide research), Letters to the Editor (comments on articles published in the journal and on other matters of interest to the field of nitric oxide research), and Announcements and Calendar (notices of forthcoming conferences, courses, and other events pertaining to nitric oxide research).
Submission of Manuscripts
Manuscripts should be written in clear, concise, and grammatical English and should be submitted in quadruplicate (one original and three photocopies), including four sets of original figures or good quality glossy prints to:
NITRIC OXIDE: Biology and Chemistry
Editorial Office
525 B Street, Suite 1900
San Diego, CA 92101-4495, USA
Phone: 619-699-6275
Fax: 619-699-6700
E-mail: nox@elsevier.com
Failure to receive the required number of copies of the manuscript may delay review. All copies of halftone artwork must be glossy prints or originals; photocopies of halftones do not show sufficient detail to be used for the review process.
Policy regarding publication of experiments on unanesthetized animals conforms with the standards for use of laboratory animals established by the Institute of Laboratory Animal Resources, U.S. National Academy of Sciences. Experiments in which curariform agents are used must be justified and details of the steps taken to reduce or avoid distress to the animal must be provided, particularly with regard to electrical stimulation.
Electronic Submission. Authors are requested to transmit the text and art of the manuscript in electronic form, via a computer disk, e-mail (nox@elsevier.com), or FTP (ftp.elsevier.com, with username anon and password essd4acc), each time a new version is submitted. Submission as an e-mail attachment is acceptable provided that all files are included in a single archive the size of which does not exceed 2 megabytes. Hard-copy printouts of the manuscript and art that exactly match the electronic files must be supplied. The manuscript will be edited according to the style of the journal, and the proofs must be read carefully by the author.
Original papers only will be considered. Manuscripts are accepted for review with the understanding that the same work has not been published, that it is not under consideration for publication elsewhere, and that its submission for publication has been approved by all of the authors and by the institution where the work was carried out. It is the responsibility of the corresponding author to obtain agreement of all the coauthors of the manuscript prior to its submission to the journal. Abstracts of oral or poster presentations are not considered to constitute previous publication. Presentation of material in preliminary communications normally will not preclude publication of a full paper in NITRIC OXIDE, provided that the full paper contains additional information that justifies its publication and does not repeat the presentation of the same data that supported the preliminary communication. The manuscript should be accompanied by copies of all preliminary communications and of all relevant manuscripts that are in press or under editorial consideration by another journal. Authors must verify the wording of any cited personal communication with the persons who supplied the information and obtain approval for the use of their names in connection with the quoted information for the citation of unpublished work; written evidence of such approval should accompany the manuscript. All material published in NITRIC OXIDE represents the opinions of the authors and should not be construed to reflect the opinions of the Editors or the Publisher.
Upon acceptance of an article, authors will be asked to transfer copyright (for more information on copyright, see http://authors.elsevier.com). This transfer will ensure the widest possible dissemination of information. A letter will be sent to the corresponding author confirming receipt of the manuscript. A form facilitating transfer of copyright will be provided after acceptance.
If material from other copyrighted works is included, the author(s) must obtain written permission from the copyright owners and credit the source(s) in the article. Elsevier has preprinted forms for use by authors in these cases: contact Elsevier Global Rights Department, P.O. Box 800, Oxford OX5 1DX, UK; phone: (+44) 1865 843830, fax: (+44) 1865 853333, e-mail: permissions@elsevier.com.
Reviews
Brief Reviews may be solicited or unsolicited. Unsolicited Brief Reviews should be submitted initially as a 2-page outline for consideration and approval by the Editors. Solicited Brief Reviews should be approximately 10 pages in length (about 25-30 double-spaced manuscript pages). A Brief Review should have an Abstract or Summary of 300-500 words.
Preparation of Manuscript
Manuscripts should be typewritten and double-spaced throughout on one side of 8 1/2 x 11-in. white paper with 1-in. margins on all sides. All pages should be numbered consecutively and organized as follows.
The title page (p. 1) should contain the article title, authors' names and complete affiliations, footnotes to the title, and the address and contact numbers (phone, fax, e-mail) of the person to whom correspondence should be sent.
An abstract (p. 2) consisting of a single paragraph of 150-250 words must be included. Keywords should be listed immediately after the abstract.
The introduction should be informative and present the background, rationale, and objective of the study. The introduction is to be prepared without subheadings.
Experimental procedures should be informative and presented in sufficient detail to enable others to conduct similar novel experiments without the necessity to refer to other references or sources.
Results and Discussion should be two separate and distinct sections, each with subheadings where appropriate. The Results section should present and explain the data in a clear manner. A detailed explanation of any illustrative data (figures, tables) should be given in the text. No discussion of the data, however, should be presented in the Results. The Discussion section should be informative and include all explanations and discussions of data. Be certain that the conclusions and any hypotheses made are derived from, and are consistent with, the data presented.
Acknowledgments should be brief and precede the Reference section.
References must include all authors' names and the title of the article. They should be cited in the text by an Arabic numeral in square brackets and listed at the end of the paper in numerical order typed double-spaced on a separate sheet. Abbreviations of journal titles should conform to those of the most recent edition of Chemical Abstracts Service Source Index. Please note the following examples.
[1] M.G. Ferrini, D. Vernet, T.R. Magee, A. Shahed, A. Qian, J. Rajfer, N.F. Gonzalez-Cadavid, Antifibrotic role of inducible nitric oxide synthase, Nitric Oxide 6 (2002) 247-352.
[2] R. Hesketh, The Oncogene FactsBook, Academic Press, San Diego, 1995.
[3] J.S. Beckman, The physiological and pathological chemistry of nitric oxide, in: J. Lancaster (Ed.), Nitric Oxide: Principles and Actions, Academic Press, San Diego, pp. 1-82.
Footnotes to the text should be identified by superscript Arabic numerals and should be typed double-spaced on a separate sheet: footnotes to tables should be identified by superscript lowercase italic letters (a,b, soft-etc.) and placed at the bottom of the table.
Tables should be numbered with Arabic numerals and cited consecutively in the text. Each table should be titled and typed double-spaced on a separate sheet. Units must be clearly indicated for each of the entries in the table. Authors can submit complex tables and mathematical material as camera-ready copy.
Figures should be cited consecutively in the text by Arabic numerals. Legends should be typed double-spaced on a separate sheet. Lettering on drawings should be of professional quality or generated by high-resolution computer graphics and should be large enough (10-12 points) to withstand appropriate reduction for publication. Please visit our Web site at http://authors.elsevier.com/artwork for detailed instructions on preparing electronic artwork.
One page of color figures will be published free of charge in each article. Additional figures in color will be published if the authors defray costs.
Suggestions for cover photographs are welcome. Submit them as prints, slides, or in electronic form (TIFF and EPS files only). A slide or electronic file should be accompanied by a print that matches it exactly. A short (one-line) legend should also accompany each photograph.
Nomenclature. All nomenclature should be simple, unambiguous, and in conformity with the conventions developed by the IUPAC. Because compound names ending in -ic and -ous are not recommended (the oxidation state is not well defined), systematic nomenclature is preferred.
Proofs
Proofs will be sent to the corresponding author, with a reprint order form. Authors will be charged for extensive alterations.
Editorial Board
-
-
Editor-in-Chief:
J.R. Lancaster Jr., Ph.D, Center for Free Radiccal Biology, The University of Alabama at Birminigham, Birmingham, Alabama, USA
Associate Editor:
U. Förstermann, MD, Ph.D, Department of Pharmacology, Johannes Gutenberg University, Mainz, Germany
Editorial Advisory Board:
J. Beckman, Ph.D, Deparment of Biochemistry and Biophysics, Oregon State University, Oregon, USA
T.R. Billiar, MD, Ph.D, Department of Surgery, University of Pittsburgh, School of Medicine, Pennsylvania, USA
J. Bonaventura, Ph.D, Duke University Marine Laboratory, North Carolina, USA
R. Busse, MD, Ph.D, Zentrum der Physiologie, Klinikum der JWG-Universität, Frankfurt am Main, Germany
G. Chaudhuri, MD, Ph.D, Department of Obstetrics & Gynecology, UCLA School of Medicine, California, USA
H.-T. Chung,, Department of Microbiology & Immunology, Wonkwang University School of Medicine, Chonbug, Korea
E.I. Closs, Ph.D, Department of Pharmacology, Johannes Gutenberg University, Mainz, Germany
T. Dawson, MD, Department of Neurology, Johns Hopkins University School of Medicine, Maryland, USA
V.L. Dawson, Ph.D, Department of Neurology, Johns Hopkins University School of Medicine, Maryland, USA
J.-C. Drapier, Ph.D, ICSN-CNRS, Gif-sur-Yvette, France
H. Drexler, MD, Department of Medicine, Hannover Medical University, Germany
V.J. Dzau, MD, Chairman, Department of Medicine, Brigham and Women's Hospital, Massachusetts, USA
M. Feelisch, Ph.D, Department of Molecular and Cellular Physiology, Louisiana State University Health Sciences Center, Louisiana, USA
B.A. Freeman, Ph.D, Department of Anesthesiology, University of Alabama at Birmingham, Alabama, USA
J.M. Fukuto, Ph.D, Department of Pharmacology, UCLA School of Medicine, Center for Health Sciences, California, USA
R.F. Furchgott, Ph.D, Department of Pharmacology, SUNY Health Sciences Center, New York, USA
O.W. Griffith, Ph.D, Department of Biochemistry, Medical College of Wisconsin, USA
S.S. Gross, Ph.D, Department of Pharmacology, Cornell University Medical College, New York, USA
D.G. Harrison, MD, Department of Medicine, Division of Cardiology, Emory University School of Medicine, Georgia, USA
M.W. Hentze, MD, Gene Expression Program, European Molecular Biology Laboratory, Heidelberg, Germany
J.B. Hibbs, MD, Division of Infectious Diseases, University of Utah School of Medicine, Utah, USA
G. Kaley, Ph.D, Department of Physiology, New York Medical College, New York, USA
L.K. Keefer, Ph.D, Laboratory of Comparative Carcinogenesis, National Cancer Institute, Frederick Cancer Research & Development Center, Maryland, USA
H. Kleinert,, Department of Pharmacology, Johannes Gutenberg University, Mainz, Germany
R. Levi, MD, Department of Pharmacology, Cornell University Medical College, New York, USA
J. Loscalzo, MD, Ph.D, University Hospital, Boston University Medical Hospital Cardiology, Massachusetts, USA
C.J. Lowenstein, MD, Departnent of Medicine, Division of Cardiology, Johns Hopkins University School of Medicine, Maryland, USA
M.A. Marletta, Ph.D, Department of Chemistry, University of California, Berkeley, California, USA
P.A. Marsden, MD, Department of Medicine, University of Toronto, St. Michael's Hospital, Ontario, Canada
F. Marumo, MD, Second Department of Internal Medicine, Tokyo Medical and Dental University, Tokyo, Japan
B.S. Masters, Ph.D, Department of Biochemistry, University of Texas Health Sciences Center, Texas, USA
B. Mayer, Ph.D, Institut f¨¹r Pharmakologie & Toxikologie, Karl Franzens Universität Graz, Austria
T. Michel, MD, Ph.D, Department of Medicine - Cardiology, Harvard Medical School, Brigham and Women's Hospital, Massachusetts, USA
A. M¨¹lsch, MD, Zentrum der Physiologie, Klinikum der JWG-Universität, Frankfurt am Main, Germany
S. Moncada, MD, Wolfson Institute for Biomedical Research, University College London, United Kingdom
M. Mori,, Department of Molecular Genetics, Kumamoto University School of Medicine, Japan
F. Murad, MD, Ph.D, Department of Integrative Biology and Pharmacology, University of Texas at Houston Medical School, Texas, USA
C.F. Nathan, MD, Department of Microbiology and Immunology, Weill Medical College, Cornell University, New York, USA
W.A. Pryor, Ph.D, Biodynamics Institute, Louisiana State University, Louisiana, USA
I. Sakuma,, Department of Cardiovascular Medicine, Hokkaido University Graduate School of Medicine, Sapporo, Japan
W.C. Sessa, Ph.D, Department of Pharmacology, Yale University School of Medicine, Connecticut, USA
S.H. Snyder, MD, Johns Hopkins University School of Medicine, Maryland, USA
J. Stamler, MD, Division of Pulmonology - Cardiology, Duke University Medical Center, North Carolina, USA
D.J. Stuehr, Ph.D, Immunology, Cleveland Clinic Foundation, Ohio, USA
S.R. Tannenbaum, Ph.D, Department of Bioengineering & Environmental Health, Massachusetts Institute of Technology, Massachusetts, USA
P.M. Vanhoutte, MD, Ph.D, Institut de Recherches, Internationales Servier, Courbevoie, France
D.A. Wink, Ph.D, National Institutes of Health, National Cancer Institute, Maryland, USA
M.W. Wolin, Ph.D, Department of Physiology, New York Medical College, New York, USA
M. Yokoyama,, First Department of Internal Medicine, Kobe University School of Medicine, Kobe, Japan
W.M. Zapol, MD, Massachusetts General Hospital, Massachusetts, USA
|
